The current recommendation of Hold for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for the last month. More
NVS
Recent Articles
3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day
With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market. More
Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade
JUNO stock has a lot going for it, but a bullish position looks a good deal better when fully-immunized with an options hedge. More
3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald’s Corporation (MCD) and Novartis AG (ADR) (NVS)
Boeing (BA) has won a dispute with Airbus, McDonald's (MCD) workers strike in the US and UK and Novartis (NVS) names Van Narasimhan its CEO. More
Novartis Wins FDA Approval for Groundbreaking Cancer Gene Therapy
Novartis (NVS) has garnered approval from the FDA for its groundbreaking cancer gene therapy, which will cost close to half a million. More
United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk
United Therapeutics (UTHR) shares skyrocketed Friday amidst rumors that the company may be the subject of a takeover by a pharma giant soon. More
Novartis AG (ADR) (NVS) Stock Pops on Solid Q2 Earnings
Novartis (NVS) stock got a boost on Tuesday with the release of positive results in its earnings report for the second quarter of 2017. More
